Get the Stockscreener App
8.67
4.62%
-0.42
After Hours:
8.67
Envveno Medical Corp stock is traded at $8.67, with a volume of 428.
It is down -4.62% in the last 24 hours and down -19.72% over the past month.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
See More
Previous Close:
$9.09
Open:
$8.67
24h Volume:
428
Relative Volume:
0.02
Market Cap:
$6.02M
Revenue:
-
Net Income/Loss:
$-18.82M
P/E Ratio:
-0.278
EPS:
-31.1883
Net Cash Flow:
$-14.79M
1W Performance:
-3.40%
1M Performance:
-19.72%
6M Performance:
-21.01%
1Y Performance:
-74.12%
1-Day Range:
$8.67
$8.67
1-Week Range:
$8.59
$9.1567
52-Week Range:
$7.01
$35.17
Envveno Medical Corp Stock (NVNO) Company Profile
Name
Envveno Medical Corp
Sector
Industry
Phone
949-261-2900
Address
70 DOPPLER, IRVINE
Compare NVNO vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corp
|
8.67 | 6.02M | 0 | -18.82M | -14.79M | -31.19 |
ABT
Abbott Laboratories
|
101.29 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.64 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.36 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.92 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.29 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Envveno Medical Corp Stock (NVNO) Latest News
Envveno Medical Stock Price Forecast. Should You Buy NVNO? - StockInvest.us
enVVeno Medical Corp (NASDAQ: NVNO) Activist Ownership Drops to Zero Following Complete Stake Sale - Kalkine Media
enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series - Yahoo Finance
About 3 million people in the U.S. are estimated to live with severe deep-vein disease. enVVeno's new videos explain it. - Stock Titan
Enveno medical director Francis Duhay sells $123 in shares By Investing.com - Investing.com Australia
Two major holders fully exit enVVeno Medical Corp (NVNO) - Stock Titan
Enveno medical director Francis Duhay sells $123 in shares - Investing.com
Director Francis Duhay Sells 11 Shares of enVVeno Medical Corp (NVNO) - GuruFocus
enVVeno Medical (NVNO) director logs small preset stock sale - Stock Titan
Director at enVVeno (NASDAQ: NVNO) plans sale of 11 shares - Stock Titan
enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand - ACCESS Newswire
A medical-device CEO's presentation is now online ahead of New York meetings - Stock Titan
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - ACCESS Newswire
EnVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference - marketscreener.com
enVVeno Medical files prospectus to offer securities for up to $100 million - scanx.trade
enVVeno Medical (NASDAQ: NVNO) readies $100M in potential securities sales - Stock Titan
Perceptive Advisors (NVNO) reports 3.5% beneficial stake via 24,605 warrants - Stock Titan
NVNO Q2 2026 Earnings: Wider-than-Expected Loss, Yet Shares Rally 8.54%Estimate Uncertainty - Vinanet
NVNO Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Development CostsEPS Consistency Score - vinanet.vn
enVVeno study shows $32,000 savings per patient for venous valve therapy - scanx.trade
enVVeno Medical (NVNO) Highlights Cost-Effectiveness of VenoValve Amid Challenging Valuation Metrics - GuruFocus
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments - ACCESS Newswire
enVVeno Study Projects About 2.2 Fewer Venous Ulcers Per Patient - Stock Titan
enVVeno cites Journal of Vascular Surgery study showing venous valve therapy saves more than $32,000 per patient over five years - Bitget
EnVVeno Moves Toward U.S. Pivotal Trial - Orange County Business Journal
enVVeno Medical receives FDA approval for pivotal trial By Investing.com - Investing.com Nigeria
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve - Weatherford Democrat
FDA IDE pivotal trial and 2027 cash runway for enVVeno Medical (NASDAQ: NVNO) - Stock Titan
NVNO Q2'26 Earnings: EPS estimate is (4.69) USD - TradingView
enVVeno Medical Corp (NVNO) Cash Flow - TradingKey
enVVeno Medical Corp expected to post a loss of $4.69 a shareEarnings Preview - TradingView
enVVeno Medical Corporation Revenue Breakdown – LS:A42085 - TradingView
enVVeno Medical Corp (NVNO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
enVVeno Medical Corp (NVNO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
enVVeno Medical Corp (NVNO) Income Statement - TradingKey
NVNO|enVVeno Medical Corp|Price:10.390|Chg%:+0.160 - TradingKey
NVNO|enVVeno Medical Corp|Price:10.320|Chg%:-0.070 - TradingKey
enVVeno Medical Corp (NVNO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NVNO Q3 2025 Earnings: Narrowing Losses Signal Cost DisciplineEarnings Expansion Phase - dars.gov.et
enVVeno Medical (NVNO) Surges 5% as Volume Spikes – Key Levels to WatchZigzag Correction - dars.gov.et
NVNO Q3 2025 Earnings: Narrower Loss Surprises as Company Advances Venous Therapy PipelineBanking Earnings Report - po-news-eg.net
enVVeno Medical (NVNO) Holds Near Support Amid Minimal Price MovementMutual Fund Flow - careplusvn.com
NVNO Q3 2025 Earnings: Narrower Loss Than Expected as enVVeno Controls CostsDividend Cut Risk - vinanet.vn
NVNO Q3 2025 Earnings: Smaller-Than-Expected Loss Signals Cost DisciplineEarnings Manipulation Risk - dars.gov.et
NVNO Q3 2025 Earnings: Narrower-than-Expected Loss Despite Stock PullbackOne-Time Gain Impact - vinanet.vn
EnVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor What This Means Segment - marketscreener.com
enVVeno Medical Updates Investors With New Presentation - The Globe and Mail
NVNO Q3 2025 Earnings: Smaller-Than-Expected Loss Boosts Investor SentimentManagement Tone Analysis - vinanet.vn
enVVeno Medical highlights newly issued U.S. patent - TipRanks
enVVeno Medical (NVNO) Secures U.S. Patent and Advances FDA Tria - GuruFocus
enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment - ACCESS Newswire
Envveno Medical Corp Stock (NVNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
0.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):